Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol

Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol

Abstract Background Multiple sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system with an increasing worldwide prevalence. Since 1993, more than 15 disease-modifying immunotherapies (DMTs) have been licenced and have shown moderate efficacy in clinical trials. Bas...

Full description

Bibliographic Details
Main Authors: Thomas Lehnert, Christian Röver, Sascha Köpke, Jordi Rio, Declan Chard, Andrea V. Fittipaldo, Tim Friede, Christoph Heesen, Anne C. Rahn
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Systematic Reviews
Subjects:
Multiple sclerosis
Systematic review
Meta-analysis
Immunotherapy
Treatment response
Subgroups
Online Access:https://doi.org/10.1186/s13643-022-01997-2

Internet

https://doi.org/10.1186/s13643-022-01997-2

Similar Items